Condition (MeSH)
Mediastinal Neoplasms
ClinicalTrials.gov lists 21 trials for Mediastinal Neoplasms or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Mediastinal Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Mediastinal Neoplasms trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2019 | 1 |
| 2018 | 4 |
| 2017 | 1 |
| 2016 | 1 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mediastinal Neoplasms trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 8 |
| Observational | 2 |
How many Mediastinal Neoplasms trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 6 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mediastinal Neoplasms trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Intuitive Surgical | 1 |
| National Cancer Institute (NCI) | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ifosfamid | 2 |
| Etoposid | 2 |
| Cisplatin 1 | 1 |
| Cytarabine IT | 1 |
| Filgrastime (G-CSF) | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Mediastinal Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 2 | 1 |
| Hypoxia | 2 | 1 |
| Infections and infestations-Other, specify infection with normal ANC or Gr 1 or 2 neutrophils:Blood | 2 | 1 |
| ANEMIA | 1 | 1 |
| Anemia | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Mediastinal Neoplasms? (112)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma. | Blood advances | 2025 | Yes |
| Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial. | Blood | 2025 | Yes |
| Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | Yes |
| Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 study. | International journal of clinical oncology | 2024 | Yes |
| Prediction Models for Mediastinal Metastasis and Its Detection by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Potentially Operable Non-Small Cell Lung Cancer: A Prospective Study. | Chest | 2023 | Yes |
Showing 5 of 112 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.